➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Mallinckrodt
Colorcon
Johnson and Johnson
McKinsey

Last Updated: January 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Bombesin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Bombesin?

Bombesin is an investigational drug.

There have been 15 clinical trials for Bombesin. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2017.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Breast Neoplasms, and Glioma. The leading clinical trial sponsors are Peking Union Medical College Hospital, National Institute for Biomedical Imaging and Bioengineering (NIBIB), and Stanford University.

There are three hundred and sixteen US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for Bombesin
TitleSponsorPhase
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate CancerStanford UniversityPhase 2
68Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast CancerGeneral ElectricPhase 1/Phase 2
68Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast CancerStanford UniversityPhase 1/Phase 2

See all Bombesin clinical trials

Clinical Trial Summary for Bombesin

Top disease conditions for Bombesin
Top clinical trial sponsors for Bombesin

See all Bombesin clinical trials

US Patents for Bombesin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Bombesin   Start Trial Water soluble membrane proteins and methods for the preparation and use thereof Massachusetts Institute of Technology (Cambridge, MA)   Start Trial
Bombesin   Start Trial Therapeutic fusion proteins Ipsen Bioinnovation Limited (Abingdon, Oxfordshire, GB)   Start Trial
Bombesin   Start Trial Radiolabeled active targeting pharmaceutical composition and the use thereof INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (Longtan Township, TW)   Start Trial
Bombesin   Start Trial Methods for screening for binding partners of G-protein coupled receptors Heptares Therapeutics Limited (Hertfordshire, GB)   Start Trial
Bombesin   Start Trial Recombinant polypeptides for membrane fusion and uses thereof Entos Pharmaceuticals Inc. (Edmonton, CA)   Start Trial
Bombesin   Start Trial Methods for quantifying polypeptides using mass spectrometry WATERS TECHNOLOGIES CORPORATION (Milford, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Bombesin

Drugname Country Document Number Estimated Expiration Related US Patent
Bombesin Australia AU2012220558 2031-02-23   Start Trial
Bombesin Australia AU2016201914 2031-02-23   Start Trial
Bombesin Australia AU2017261525 2031-02-23   Start Trial
Bombesin Brazil BR112013020969 2031-02-23   Start Trial
Bombesin Canada CA2827187 2031-02-23   Start Trial
Bombesin Chile CL2013002419 2031-02-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Mallinckrodt
Colorcon
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.